RESUMEN
The population pharmacokinetics of atovaquone were examined in 458 black, Oriental, and Malay patients with acute Plasmodium falciparum malaria receiving atovaquone alone or concomitantly with other drugs. Oral clearance (CL/F) showed a 0.674 power relationship with weight and is similar in Oriental and Malay subjects but 58.5% lower in black subjects. On the basis of mean body weight, the population estimate of CL/F is 3.28, 8.49, and 9.13 L/hr in black, Oriental, and Malay subjects, respectively. The relationship between apparent volume of distribution (V area/F) and weight was linear and similar in all three races at 7.98 L/kg. The population estimate of V area/F is 345, 383, and 428 L in black, Oriental, and Malay subjects, respectively. The bioavailability of the high and low doses of atovaquone was similar. Neither CL/F nor V area/F were significantly affected by age, gender, and the coadministration with chloroguanide (proguanil), pyrimethamine, and tetracycline. Half-life (t1/2) showed a 0.326 power relationship with weight; thus, the population estimate of t1/2 in black, Oriental, and Malay subjects is 72.9, 31.3, and 32.5 hours, respectively. The final magnitudes of interpatient variability in CL/F and V area/F were 68% and 49%, respectively.
Asunto(s)
Antimaláricos/farmacocinética , Malaria Falciparum/tratamiento farmacológico , Naftoquinonas/farmacocinética , Adolescente , Adulto , Análisis de Varianza , Antimaláricos/sangre , Antimaláricos/uso terapéutico , Atovacuona , Niño , Preescolar , Simulación por Computador , Bases de Datos Factuales , Relación Dosis-Respuesta a Droga , Femenino , Gabón , Humanos , Kenia , Malaria Falciparum/sangre , Malaria Falciparum/metabolismo , Masculino , Persona de Mediana Edad , Modelos Biológicos , Naftoquinonas/sangre , Naftoquinonas/uso terapéutico , Filipinas , Tailandia , ZambiaRESUMEN
BACKGROUND: Malaria is a major cause of pediatric mortality in sub-Saharan Africa. Worldwide estimates of mortality among children with Plasmodium falciparum malaria range from 1 to 2 million deaths per year. Management of malaria is increasingly difficult because of the global spread of drug-resistant strains of P. falciparum. There is an urgent need for safe and effective new therapies to treat multidrug-resistant malaria. METHODS: This open label, randomized trial compared atovaquone and proguanil hydrochloride with halofantrine for treatment of acute, uncomplicated P. falciparum malaria in children age 3 to 12 years (84 patients per group). Study drug dosages were adjusted by weight (approximately 20 and 8 mg/kg daily for three doses for atovaquone and proguanil hydrochloride and 8 mg/kg every 6 h for three doses for halofantrine). Patients were monitored by serial clinical and laboratory assessments for 28 days after starting treatment. RESULTS: Both regimens were effective (cure rate, 93.8% for atovaquone and proguanil hydrochloride and 90.4% for halofantrine) and produced prompt defervescence. Mean parasite clearance times were 50.2 h for halofantrine and 64.9 h for atovaquone and proguanil hydrochloride. More adverse experiences were reported in children treated with halofantrine (119) than with atovaquone and proguanil hydrochloride (73). CONCLUSIONS: In Kenyan children the combination of atovaquone and proguanil hydrochloride has efficacy comparable with that of halofantrine for treatment of acute uncomplicated multidrug-resistant falciparum malaria and is associated with a lower rate of adverse events.
Asunto(s)
Antimaláricos/uso terapéutico , Malaria Falciparum/tratamiento farmacológico , Naftoquinonas/uso terapéutico , Fenantrenos/uso terapéutico , Proguanil/uso terapéutico , Enfermedad Aguda , Animales , Atovacuona , Niño , Preescolar , Quimioterapia Combinada , Heces/parasitología , Femenino , Humanos , Masculino , Plasmodium falciparum/aislamiento & purificación , Resultado del TratamientoRESUMEN
The continuing spread of drug-resistant malaria emphasizes the need for new antimalarial drugs. Atovaquone is a broad-spectrum antiprotozoal drug with a novel mechanism of action, via inhibition of parasite mitochondrial electron transport, and a favorable safety profile. Early studies with atovaquone alone for treatment of malaria demonstrated good initial control of parasitemia but an unacceptable rate of recrudescent parasitemia. Parasites isolated during recrudescence after treatment with atovaquone alone were resistant to atovaquone in vitro. The combination of atovaquone and proguanil is synergistic in vitro, and clinical studies demonstrated enhanced efficacy of the combination compared to either drug alone for treatment of malaria. Malarone, a fixed-dose combination of 250 mg of atovaquone and 100 mg of proguanil hydrochloride, is available in many countries for treatment of acute, uncomplicated malaria caused by Plasmodium falciparum. At the recommended dose (in adults, four tablets once a day for three days), the overall cure rate was > 98% in more than 500 patients with falciparum malaria. In four randomized, controlled clinical trials, treatment with atovaquone and proguanil hydrochloride was significantly more effective than mefloquine (Thailand), amodiaquine (Gabon), chloroquine (Peru and the Philippines) or chloroquine plus pyrimethamine/sulfadoxine (Philippines). In clinical trials where the comparator drug was highly effective, treatment with atovaquone and proguanil hydrochloride was equally effective. Parasites isolated during recrudescence after treatment with the combination of atovaquone and proguanil were not resistant to atovaquone in vitro. The most commonly reported adverse events in clinical trials (abdominal pain, anorexia, nausea, vomiting, diarrhea and coughing) occurred with similar frequency in patients treated with a comparator drug. Malarone is a safe and effective new agent for treatment of malaria.
Asunto(s)
Antimaláricos/uso terapéutico , Malaria Falciparum/tratamiento farmacológico , Naftoquinonas/uso terapéutico , Proguanil/uso terapéutico , Adulto , Anciano , Antimaláricos/administración & dosificación , Antimaláricos/efectos adversos , Atovacuona , Niño , Combinación de Medicamentos , Quimioterapia Combinada , Humanos , Naftoquinonas/administración & dosificación , Naftoquinonas/efectos adversos , Proguanil/administración & dosificación , Proguanil/efectos adversos , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
The therapy of Plasmodium falciparum malaria continues to be a problem in many parts of Southeast Asia because of multidrug resistance to nearly all existing antimalarial drugs. Atovaquone is a novel hydroxynaphthoquinone with broad spectrum anti-protozoal activity. We recently evaluated the antimalarial activity of atovaquone in a series of dose-ranging studies in 317 patients with malaria at the Bangkok Hospital for Tropical Diseases. Originally, the drug was administered alone. Using atovaquone alone resulted in satisfactory, initial clinical responses in all patients; the mean parasite and fever clearance times were 62 and 53 hr, respectively. However, irrespective of the duration of therapy, overall cure rates were approximately 67%. In vitro sensitivity studies on parasites taken from patients prior to treatment and at the time of recrudescence showed a marked decrease in susceptibility to atovaquone in the recrudescent parasites. To improve cure rates, atovaquone was administered in combination with other drugs with antimalarial activity. Proguanil and tetracycline were chosen due to laboratory evidence of potentiation; doxycycline was selected because it has a longer half-life than tetracycline. Although pyrimethamine did not show laboratory evidence of potentiation with atovaquone, it was chosen as an alternative inhibitor of dihydrofolic acid reductase with a longer half-life than proguanil. The clinical studies with these drug combinations confirmed the laboratory results with marked improvement in cure rates for proguanil, tetracycline, and doxycycline; pyrimethamine showed only minimal improvement. Proguanil was subsequently selected as the preferred drug partner because of its long record of safety and the ability to use the drug in pregnant women and children. Of the 104 patients with falciparum malaria treated with atovaquone plus proguanil for 3-7 days, 101 were cured and had virtually no adverse side effects. The combination of atovaquone and proguanil also was effective in eliminating erythrocytic forms of P. vivax, but parasitemia recurred in most patients.
Asunto(s)
Antimaláricos/uso terapéutico , Malaria Falciparum/tratamiento farmacológico , Naftoquinonas/uso terapéutico , Enfermedad Aguda , Adolescente , Adulto , Anciano , Atovacuona , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Naftoquinonas/administración & dosificaciónRESUMEN
The increasing frequency of therapeutic failures in falciparum malaria underscores the need for novel, rapidly effective antimalarial drugs or drug combinations. Atovaquone and proguanil are blood schizonticides that demonstrate synergistic activity against multi-drug-resistant Plasmodium falciparum in vitro. In an open-label, randomized, controlled clinical trial conducted in Thailand, adult patients with acute P. falciparum malaria were randomly assigned to treatment with atovaquone and proguanil/hydrochloride (1,000 mg and 400 mg, respectively, administered orally at 24-hr intervals for three doses) or mefloquine (750 mg administered orally, followed 6 hr later by an additional 500-mg dose). Efficacy was assessed by cure rate (the percentage of patients in whom parasitemia was eliminated and did not recur during 28 days of follow-up), parasite clearance time (PCT), and fever clearance time (FCT). Safety was assessed by sequential clinical and laboratory assessments for 28 days. Atovaquone/proguanil was significantly more effective than mefloquine (cure rate 100% [79 of 79] vs. 86% [68 of 79]; P < 0.002). The atovaquone/proguanil and mefloquine treatments did not differ with respect to PCT (mean = 65 hr versus 74 hr) or FCT (mean = 59 hr versus 51 hr). Adverse events were generally typical of malaria symptoms and each occurred in < 10% of the patients in either group, with the exception of increased vomiting found in the atovaquone/proguanil group. Transient elevations of liver enzyme levels occurred more frequently in patients treated with atovaquone/proguanil than with mefloquine, but the differences were not significant and values returned to normal by day 28 in most patients. The combination of atovaquone and proguanil was well tolerated and more effective than mefloquine in the treatment of acute uncomplicated multidrug-resistant falciparum malaria in Thailand.
Asunto(s)
Antimaláricos/uso terapéutico , Malaria Falciparum/tratamiento farmacológico , Mefloquina/uso terapéutico , Naftoquinonas/uso terapéutico , Proguanil/uso terapéutico , Enfermedad Aguda , Adolescente , Adulto , Antimaláricos/efectos adversos , Atovacuona , Combinación de Medicamentos , Femenino , Humanos , Malaria Falciparum/sangre , Masculino , Mefloquina/efectos adversos , Persona de Mediana Edad , Naftoquinonas/efectos adversos , Proguanil/efectos adversos , Tailandia , Resultado del TratamientoRESUMEN
Atovaquone and proguanil hydrochloride are blood schizonticides that demonstrate in vitro synergy against drug-resistant strains of Plasmodium falciparum. When coadministered, they may therefore be effective for the treatment of malaria in regions where there is known or suspected drug resistance. In an open-label, randomized, parallel-group, clinical trial conducted in Zambia, 163 patients (age range, 14 to 54 years) with acute P falciparum malaria were randomly assigned to receive treatment with atovaquone and proguanil hydrochloride (1000 and 400 mg, respectively, administered orally at 24-hour intervals for 3 doses; n = 82) or pyrimethamine/sulfadoxine (75/1500 mg administered orally as a single dose; n = 81). Efficacy was assessed by cure rate (the percentage of patients in whom parasitemia was eliminated and did not recur during 28 days of follow-up), parasite clearance time (PCT), and fever clearance time (FCT). Safety was determined by sequential clinical and laboratory assessments over 28 days. Cure rates did not differ significantly between patients treated with atovaquone and proguanil (100%) and those treated with pyrimethamine/sulfadoxine (98.8%). Patients in the atovaquone and proguanil group had a significantly shorter FCT than patients in the pyrimethamine/sulfadoxine group (mean, 30.4 vs 44.9 hours; P < 0.05) but a longer PCT (mean, 64.0 vs 51.4 hours; P < 0.05). Both treatments were well tolerated; adverse events and laboratory abnormalities were typical of those normally observed in patients with malaria. In this study, the combination of atovaquone and proguanil was equally effective and as well tolerated as pyrimethamine/sulfadoxine for the treatment of acute, uncomplicated, drug-resistant falciparum malaria in Zambia.
Asunto(s)
Malaria Falciparum/tratamiento farmacológico , Plasmodium falciparum/efectos de los fármacos , Proguanil/uso terapéutico , Pirimetamina/uso terapéutico , Sulfadoxina/uso terapéutico , Adolescente , Adulto , Animales , Células Sanguíneas/efectos de los fármacos , Células Sanguíneas/parasitología , Análisis Químico de la Sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Polifarmacia , Pirimetamina/efectos adversos , Sulfadoxina/efectos adversos , ZambiaRESUMEN
A trial was conducted in 32 Thai children with uncomplicated multidrug-resistant falciparum malaria to assess the efficacy, safety and pharmacokinetics of atovaquone and proguanil; plasma concentrations of atovaquone, proguanil and its metabolite, cycloguanil, were measured in a subset of 9 children. The children received atovaquone (17 mg/kg/d for 3 d) plus proguanil (7 mg/kg/d for 3 d). Twenty-six children who had only Plasmodium falciparum infection and remained in hospital for 28 d were assessed for drug efficacy. The combination regimen produced a cure rate of 100%. Parasite and fever clearance times were 47 h (range 8-75) and 50 h (range 7-111), respectively. Atovaquone and proguanil were rapidly absorbed, with median time to peak concentrations of 6 h (range 6-24) and 6 h (range 6-12), respectively. Peak concentrations of cycloguanil were achieved between 6 and 12 h (median 6) after administration of proguanil. Mean peak plasma concentration of atovaquone on day 3 was 5.1 micrograms/mL (SD = 2.1). The day 3 mean peak plasma concentration of proguanil was 306 ng/mL (SD = 108) compared with 44.3 ng/mL (SD = 27.3) for cycloguanil. Mean values for the AUC (area under plasma concentration-time curve) were 161.8 micrograms/mL.h (SD = 126.9) for atovaquone, 4646 ng/mL.h (SD = 1226) for proguanil, and 787 ng/mL.h (SD = 397) for cycloguanil. Terminal elimination half-lives of atovaquone, proguanil and cycloguanil were estimated as 31.8 h (SD = 8.9), 14.9 h (SD = 3.3) and 14.6 h (SD = 2.6), respectively. No major adverse effect was attributable to the study drugs. Atovaquone/proguanil combination is safe and highly effective, and should be especially valuable for treatment of multidrug-resistant falciparum malaria.
Asunto(s)
Antimaláricos/uso terapéutico , Malaria Falciparum/tratamiento farmacológico , Naftoquinonas/uso terapéutico , Parasitemia/tratamiento farmacológico , Proguanil/uso terapéutico , Antimaláricos/farmacocinética , Atovacuona , Niño , Resistencia a Múltiples Medicamentos , Quimioterapia Combinada , Femenino , Humanos , Malaria Falciparum/metabolismo , Masculino , Naftoquinonas/farmacocinética , Proguanil/farmacocinética , Estudios Prospectivos , Triazinas/farmacocinéticaRESUMEN
OBJECT: Clinical microdialysis enables monitoring of the cerebral extracellular chemistry of neurosurgical patients. Introduction of the technique into different hospitals' neurosurgical units has resulted in variations in the method of application. There are several variables to be considered, including length of the catheter membrane, type of perfusion fluid, flow rate of perfusion fluid, and on-line compared with delayed analysis of samples. The objects of this study were as follows: 1) to determine the effects of varying catheter characteristics on substance concentration; 2) to determine the relative recovery and true extracellular concentration by varying the flow rate and extrapolating to zero flow; and 3) to compare substance concentration obtained using a bedside enzyme analyzer with that of off-line high-performance liquid chromatography (HPLC). METHODS: A specially designed bolt was used to conduct two adjacent microdialysis catheters into the frontal cortex of patients with head injury or poor-grade subarachnoid hemorrhage who were receiving ventilation. One reference catheter (10-mm membrane, perfused with Ringer's solution at 0.3 microl/minute) was constant for all studies. The other catheter was varied in terms of membrane length (10 mm or 30 mm), perfusion fluid (Ringer's solution or normal saline), and flow rate (0.1-1.5 microl/minute). The effect of freezing the samples on substance concentration was established by on-line analysis and then repeated analysis after storage at -70 degrees C for 3 months. Samples assayed with the bedside enzyme analyzer were reassessed using HPLC for the determination of glutamate concentrations. CONCLUSIONS: Two adjacent microdialysis catheters that were identical in membrane length, perfusion fluid, and flow rate showed equivalent results. Variations in perfusion fluid and freezing and thawing of samples did not result in differences in substance concentration. Catheter length had a significant impact on substance recovery. Variations in flow rate enabled the relative recovery to be calculated using a modification of the extrapolation-to-zero-flow method. The recovery was approximately 70% at 0.3 microl/minute and 30% at 1 microl/minute (10-mm membrane) for all analytes. Glutamate results obtained with the enzyme analyzer showed good correlation with those from HPLC.
Asunto(s)
Química Encefálica , Lesiones Encefálicas/diagnóstico , Catéteres de Permanencia , Microdiálisis/instrumentación , Monitoreo Fisiológico/instrumentación , Hemorragia Subaracnoidea/diagnóstico , Adulto , Glucemia/análisis , Química Encefálica/fisiología , Lesiones Encefálicas/fisiopatología , Cromatografía Líquida de Alta Presión/instrumentación , Cuidados Críticos , Espacio Extracelular/química , Espacio Extracelular/fisiología , Lóbulo Frontal/química , Lóbulo Frontal/fisiopatología , Ácido Glutámico/análisis , Humanos , Presión Intracraneal/fisiología , Ácido Láctico/análisis , Sistemas en Línea/instrumentación , Ácido Pirúvico/análisis , Hemorragia Subaracnoidea/fisiopatologíaRESUMEN
The aim of the study was to monitor brain metabolism during aneurysm clipping using microdialysis and multiparameter sensors, particularly to investigate the effects of temporary clipping of vessels. Microdialysis catheters (n = 10) and Paratrend brain multiparameter (O2, CO2, pH and temperature) sensors (n = 15) were inserted into the cerebral cortex via a specially designed triple bolt prior to craniotomy. Baseline brain O2 levels ranging from 15-45 mmHg (2.0-6.0 kPa) and glucose levels from 0.5-3 mmol l-1 were stable during uneventful periods. The mean lactate/pyruvate (L/P) ratio ranged from 32 to 65 (normal < 30), indicating a tendency towards anerobic metabolism in all patients. Overall, short periods of temporary clipping (< 3 min; n = 6) were well tolerated producing no significant reduction in brain O2 (pre-clip mean 23 mmHg (3.0 kPa) vs. post-clip mean 20 mmHg (2.6 kPa)) or elevation of the L/P ratio (pre-clip mean 42 vs. post-clip mean 43). Two patients with prolonged temporary clipping showed derangements in the Paratrend parameters associated with increases in the L/P ratio. The results demonstrated that the monitored variables remained stable during uneventful procedures, including transient temporary clipping, but adverse events such as prolonged temporary clipping resulted in pronounced changes in brain metabolism. Monitoring of metabolism during aneurysm surgery may be of benefit in selected patients.
Asunto(s)
Encéfalo/metabolismo , Encéfalo/cirugía , Aneurisma Intracraneal/cirugía , Microdiálisis/métodos , Monitoreo Intraoperatorio/instrumentación , Hemorragia Subaracnoidea/cirugía , Adulto , Anciano , Diseño de Equipo , Femenino , Humanos , Aneurisma Intracraneal/complicaciones , Masculino , Persona de Mediana Edad , Consumo de Oxígeno/fisiología , Hemorragia Subaracnoidea/etiología , Instrumentos Quirúrgicos , Factores de Tiempo , Resultado del TratamientoRESUMEN
Head injury is associated with complex pathophysiological changes in metabolism. The objective of the study was to investigate these changes by applying on-line bedside monitoring of cerebral metabolism using microdialysis. Following approval by the Local Ethics Committee and consent from the next of kin, a microdialysis catheter was inserted into the frontal cortex of patients with severe head injury. Twenty-one patients were studied for 102.3 +/- 26.9 hours (mean +/- 95% confidence interval; total 89.4 patient monitoring days). The overall cerebral glucose (mean of means) was 1.63 +/- 0.31 mM with periods of undetectable glucose recorded. The cerebral lactate and lactate/pyruvate ratio were 4.69 +/- 0.61 mM and 29.9 +/- 3.73 respectively. Patients who died (n = 4) or who were severely disabled (not proceeding to rehabilitation, n = 5) had a tendency towards lower glucose (1.39 +/- 0.35 mM), higher lactate (5.10 +/- 1.02 mM) and higher lactate/pyruvate ratios (35.5 +/- 7.67) compared to patients with good outcome (home or proceeding to rehabilitation, n = 12, glucose 1.80 +/- 0.49 mM, lactate 4.38 +/- 0.85 mM, lactate/pyruvate ratio 27.9 +/- 4.33). Trends in these metabolic parameters relating to outcome were identifiable. In the majority of patients, cerebral glutamate levels (overall mean of means 9.47 +/- 4.59 microM) were initially high and then declined to stable levels. Patients in whom the glutamate level remained elevated or in whom secondary rises in glutamate were seen had a poor outcome. The application of bedside analysis of microdialysis enables the progress of the patient to be monitored on-line. In addition to establishing trends of improving and deteriorating metabolism, the technique has the potential to monitor the effects of therapeutic manoeuvres on the biochemistry.
Asunto(s)
Lesiones Encefálicas/diagnóstico , Catéteres de Permanencia , Metabolismo Energético/fisiología , Microdiálisis/instrumentación , Monitoreo Fisiológico/instrumentación , Sistemas en Línea , Adolescente , Adulto , Anciano , Glucemia/metabolismo , Lesiones Encefálicas/mortalidad , Lesiones Encefálicas/fisiopatología , Femenino , Lóbulo Frontal/lesiones , Lóbulo Frontal/fisiopatología , Ácido Glutámico/metabolismo , Humanos , Ácido Láctico/metabolismo , Masculino , Persona de Mediana Edad , Pronóstico , Ácido Pirúvico/metabolismo , Tasa de SupervivenciaRESUMEN
566C80 is a novel hydroxynaphthoquinone with broad-spectrum anti-parasitic properties. In vitro the compound was more potent against Plasmodium falciparum than any of the established anti-malarial drugs. It had good activity against the pathogen in Aotus monkeys and was also effective in rodents infected with various drug-resistant strains of P. yoelii and P. berghei. In mice the compound showed significant activity against Toxoplasma gondii. Evaluation of the metabolic stability of 566C80 to NADPH-mediated oxidative metabolism was made using microsome preparations from a number of species including man. Unlike other quinones examined, 566C80 was shown to be inert in these assays. In Phase 1 clinical studies up to 750mg of compound were given as a single oral dose to fasted healthy male adults. This was well tolerated and the plasma drug elimination half-life was approximately 70h. In these subjects a 450mg dose gave plasma concentrations of 0.1-0.3 micrograms/ml which were achieved 1 h post-dosing and remained so for at least 7 days. Volunteers ingesting food prior to drug administration had quinone plasma levels which were significantly higher. Phase II trials are now underway to assess 566C80 for use against malaria and opportunistic infections in AIDS patients.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/complicaciones , Antiinfecciosos/metabolismo , Malaria Falciparum/tratamiento farmacológico , Naftoquinonas/metabolismo , Infecciones Oportunistas/tratamiento farmacológico , 4-Quinolonas , Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Adulto , Animales , Antiinfecciosos/farmacocinética , Antiinfecciosos/farmacología , Antimaláricos/metabolismo , Antimaláricos/farmacocinética , Antimaláricos/farmacología , Aotus trivirgatus , Atovacuona , Perros , Humanos , Malaria Falciparum/metabolismo , Masculino , Microsomas Hepáticos/metabolismo , Persona de Mediana Edad , NADP/metabolismo , Naftoquinonas/farmacocinética , Naftoquinonas/farmacología , Infecciones Oportunistas/etiología , Plasmodium/efectos de los fármacos , Ratas , Toxoplasma/efectos de los fármacosRESUMEN
The efficacy and safety of a fixed-dose combination of atovaquone and proguanil hydrochloride (Malarone) were compared with chloroquine or pyrimethamine/sulfadoxine in patients with acute falciparum malaria in northern Peru. Patients were initially randomized to receive 1,000 mg atovaquone and 400 mg proguanil hydrochloride daily for 3 days (n=15) or 1,500 mg chloroquine (base) over a 3 day period (n=14) (phase 1). The cure rate with chloroquine was lower than expected and patients were subsequently randomized to receive a single dose of 75 mg pyrimethamine and 1,500 mg sulfadoxine (n=9) or atovaquone/proguanil as before (n=5) (phase 2). In phase 1, atovaquone/proguanil was significantly more effective than chloroquine (cure rate 100% [14/14] vs. 8% [1/13], P<0.0001). In phase 2, atovaquone/proguanil and pyrimethamine/sulfadoxine were both highly effective (cure rates 100% [5/5] and 100% [7/7]). There were no significant differences between treatment groups in parasite or fever clearance times. Adverse events were typical of malarial symptoms and did not differ significantly between groups. Overall efficacy of atovaquone/proguanil was 100% for treatment of acute falciparum malaria in a region with a high prevalence of chloroquine resistance.
Asunto(s)
Antimaláricos/uso terapéutico , Cloroquina/uso terapéutico , Malaria Falciparum/tratamiento farmacológico , Naftoquinonas/uso terapéutico , Proguanil/uso terapéutico , Pirimetamina/uso terapéutico , Sulfadoxina/uso terapéutico , Adolescente , Adulto , Anciano , Animales , Antimaláricos/efectos adversos , Atovacuona , Cloroquina/efectos adversos , Combinación de Medicamentos , Farmacorresistencia Microbiana , Quimioterapia Combinada , Femenino , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Naftoquinonas/efectos adversos , Perú , Proguanil/efectos adversos , Pirimetamina/efectos adversos , Sulfadoxina/efectos adversos , Resultado del TratamientoAsunto(s)
Antimaláricos/uso terapéutico , Resistencia a Múltiples Medicamentos , Malaria Falciparum/tratamiento farmacológico , Naftoquinonas/uso terapéutico , Proguanil/uso terapéutico , Adulto , Animales , Antimaláricos/farmacología , Atovacuona , Humanos , Masculino , Plasmodium falciparum/efectos de los fármacosRESUMEN
The status of trimethoprim-sulfamethoxazole (TMP-SMZ) as a chemotherapeutic agent for malaria, toxoplasmosis, and pediculosis is reviewed. The use of TMP-SMZ may be advocated for the treatment of malaria when concurrent bacterial infections are present or when conventional antimalarial agents are not available. Present evidence suggests that TMP-SMZ is effective in the treatment of toxoplasmosis; however, its role in treatment of this disease requires study. Although TMP-SMZ can eliminate head louse infections, topical insecticidal preparations are the preferred treatment.
Asunto(s)
Infestaciones por Piojos/tratamiento farmacológico , Malaria/tratamiento farmacológico , Sulfametoxazol/uso terapéutico , Toxoplasmosis/tratamiento farmacológico , Trimetoprim/uso terapéutico , Combinación de Medicamentos/uso terapéutico , Antagonistas del Ácido Fólico , Humanos , Plasmodium falciparum , Combinación Trimetoprim y SulfametoxazolRESUMEN
Twenty-one cases of agranulocytosis following dosage with one tablet of Maloprim given once or twice weekly are reviewed. Of the 18 individuals for whom the dose is certain 12 were taking twice-weekly Maloprim. Time of onset was 7-9 weeks in 15 of 19 cases where duration of dosage is known. Nine patients died, 12 recovered. Of those who died six were taking Maloprim twice weekly, one once weekly and two at an uncertain dosage. The available data suggest that this is an idiosyncratic reaction to dapsone exacerbated by the concomitant administration of pyrimethamine.
Asunto(s)
Agranulocitosis/inducido químicamente , Antimaláricos/efectos adversos , Dapsona/efectos adversos , Pirimetamina/efectos adversos , Adulto , Dapsona/metabolismo , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos/efectos adversos , Femenino , Deficiencia de Glucosafosfato Deshidrogenasa/complicaciones , Glutatión/deficiencia , Semivida , Humanos , Cinética , Masculino , Persona de Mediana EdadRESUMEN
Of 15 species of fungi examined for their ability to hydroxylate biphenyl, 10 produced 4-hydroxybiphenyl. Seven of the 10 also produced 4,4'-dihydroxybiphenyl. The most efficient strains, Absidia pseudocylindrospora NRRL 2770 and Absidia sp. NRRL 1341, were more closely examined to determine their growth characteristics and the kinetics of biphenyl hydroxylation in batch fermentation. In the absence of biphenyl, A. pseudocylindrospora 2770 and Absidia sp. 1341 grew about as rapidly and efficiently in a defined glucose minimal medium as in a complex medium. Substrate yield coefficients for glucose in both media were 0.4 to 0.5 g of biomass per g of glucose, and the specific growth rate was about 0.17 h (doubling time, about 4 h). In this unoptimized system, 10 to 15 g of biomass per liter (dry weight) could be produced, using a defined salt solution and glucose as sole carbon and energy source. In the presence of biphenyl, growth was inhibited, more so for strain 1341 than for strain 2770. However, the specific activity for biphenyl hydroxylation (milligrams of biphenol per gram of biomass) was about 3.5 times greater for strain 1341. Furthermore, biphenyl hydroxylation appeared to require the presence of an oxidizable carbon and energy source (and perhaps growth) to proceed and, at least for strain 1341, hydroxylation seemed to be more efficient in the complex medium.
RESUMEN
1. The pharmacokinetics of proguanil were evaluated in patients with acute P. falciparum malaria receiving concomitantly proguanil hydrochloride and atovaquone. The population consisted of 203 Blacks, 112 Orientals and 55 Malays; 274 males and 96 females. Of the 370 patients, 114 and 256 patients were classified as 'poor' and 'extensive' metabolizers of proguanil, respectively. Body weight and age ranged between 11-110 kg and 3-65 years, respectively. 2. A one compartment model with first-order absorption and elimination was fitted to proguanil plasma concentration-time profiles, using non-linear mixed effect modelling (NONMEM). 3. Oral clearance (CLo) showed a 0.785 power relationship with body weight and was 13% higher in Orientals than Blacks and Malays and 17% lower in 'poor' than 'extensive' metabolizers. According to the mean weight of each population, the final population estimates of CLo in Blacks, Orientals and Malays who are 'extensive' metabolizers were 54.0, 61.5 and 64.3 l h-1, respectively. Age, gender and dose had no significant effects on CLo. 4. Apparent volume of distribution (V/F) showed a 0.88 power relationship with body weight. The final population estimates were 562 and 1629 l in children (< or = 15 years) and patients aged > 15 years, respectively, who had a mean body weight of 22.6 and 54.8 kg, respectively. The effect of other covariates on V/F was not examined. 5. The final magnitudes of interpatient variability in CLo and V/F were relatively low at 22.5 and 17.0%, respectively. 6. Population pharmacokinetic parameter estimates in Black, Oriental and Malay patients with acute P. falciparum malaria are in good agreement with results of pharmacokinetic studies in healthy Caucasian volunteers. In view of the 30-50% residual variability in proguanil plasma concentrations, the slight effects of Orientals and 'poor' metabolizers on CLo are unlikely to be clinically significant. Hence, dose recommendation will be solely based on body weight.